Alemtuzumab Induction Therapy in Kidney Transplantation: A Systematic Review and Meta-Analysis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Transplantation

• Publication date

  2012-06-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/TP.0b013e318257ad41PMID 22660659
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

  2014cited by this paper
• Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

  2011cited by this paper
• Alemtuzumab for the prevention and treatment of graft-versus-host disease

  2011cited by this paper
• Alemtuzumab induction in renal transplantation.

  2011influential reference
• Kidney Transplantation With Minimized Maintenance: Alemtuzumab Induction With Tacrolimus Monotherapy—An Open Label, Randomized Trial

  2011influential reference
• Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

  2011cited by this paper
• Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.

  2011influential reference
• Current trend of induction and maintenance treatment in positive panel-reactive antibody patients: a report on OPTN/UNOS kidney transplant registry data.

  2011cited by this paper
• Alemtuzumab in the treatment of relapsing–remitting multiple sclerosis

  2010cited by this paper
• Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation.

  2010influential reference
• Induction Immunosuppression Improves Long-Term Graft and Patient Outcome in Organ Transplantation: An Analysis of United Network for Organ Sharing Registry Data

  2010influential reference
• Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis.

  2009cited by this paper
• A Randomized Trial of Alemtuzumab Versus Antithymocyte Globulin Induction in Renal and Pancreas Transplantation

  2009influential reference
• Alemtuzumab (Campath‐1H) and Tacrolimus Monotherapy After Renal Transplantation: Results of a Prospective Randomized Trial

  2008cited by this paper
• Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

  2008cited by this paper
• Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.

  2007cited by this paper
• A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow‐up

  2007influential reference
• Alemtuzumab Induction in Deceased Donor Kidney Transplantation

  2007cited by this paper
• Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients.

  2007cited by this paper
• A randomized trial of alemtuzumab vs. anti‐thymocyte globulin induction in renal and pancreas transplantation

  2007cited by this paper
• Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With Alemtuzumab

  2007influential reference
• Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody.

  2007cited by this paper
• Autoimmune Thyroid Disease After Renal Transplantation Using Depletional Induction with Alemtuzumab1

  2006cited by this paper
• The evolving role of alemtuzumab (Campath‐1H) for immunosuppressive therapy in organ transplantation

  2006cited by this paper
• Alemtuzumab (Campath-1H): A Systematic Review in Organ Transplantation

  2006cited by this paper
• Risk Factors for Development of New-Onset Diabetes Mellitus After Kidney Transplantation

  2006cited by this paper
• Campath-1H Induction and the Incidence of Infectious Complications in Adult Renal Transplantation

  2006cited by this paper
• Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab.

  2006cited by this paper
• Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years

  2005cited by this paper
• Randomized Trial of Alemtuzumab for Prevention of Graft Rejection and Preservation of Renal Function after Kidney Transplantation1

  2005influential reference
• Fungal infections in transplant recipients receiving alemtuzumab.

  2005cited by this paper
• Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report

  2004cited by this paper
• Alemtuzumab: a novel monoclonal antibody

  2001cited by this paper
• Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.

  1999cited by this paper
• The Banff 97 working classification of renal allograft pathology.

  1999cited by this paper
• Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.

  1998cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• The CAMPATH-1 antigen (CDw52).

  1990cited by this paper

• Impact of Immunosenescence in Older Kidney Transplant Recipients: Associated Clinical Outcomes and Possible Risk Stratification for Immunosuppression Reduction

  2024cites this paper
• Transplant Candidates of 70+ Years Have Superior Survival If Receiving Pre-Emptively a Living Donor Kidney

  2024cites this paper
• Rabbit anti-thymocyte globulin (rATG) as induction immunosuppression therapy in patients undergoing renal transplantation: Clinical experience from RISE registry

  2023cites this paper
• Therapy in the Course of Kidney Graft Rejection—Implications for the Cardiovascular System—A Systematic Review

  2023cites this paper
• The use of lymphocyte-depleting antibodies in specific populations of kidney transplant recipients: A systematic review and meta-analysis.

  2023cites this paper
• Interventions Against Posttransplantation Diabetes: A Scientific Rationale for Treatment Hierarchy Based on Literature Review.

  2022cites this paper
• Alemtuzumab in renal transplantation. Reviews of literature and usage in the United Kingdom.

  2022cites this paper
• The Puzzle of Immunosuppressive Drugs

  2021cites this paper
• Adverse Effects of Immunosuppression: Infections.

  2021cites this paper
• Infectious Challenges with Novel Antibody–Based Therapies

  2021cites this paper
• Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics

  2020cites this paper
• Changing Definition of Immunosuppression: Targeted Therapies and Resulting Emerging Infections and Their Prevention

  2020cites this paper
• Alteraciones del metabolismo de la glucosa en donante y receptor

  2020cites this paper
• Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients

  2020cites this paper
• Direct T-cell Inhibition and Agents Targeting T-cell Migration and Chemotaxis.

  2020cites this paper
• Outcomes of induction antibody therapies in the nonbroadly sensitized adult deceased donor kidney transplant recipients: a retrospective cohort registry analysis

  2020cites this paper
• Economic impacts of alternative kidney transplant immunosuppression: A national cohort study

  2020cites this paper
• The Impact of Different Induction Immunosuppressive Therapy on Long-Term Kidney Transplant Function When Measured by Iothalamate Clearance

  2020cites this paper
• The Impact of Different Induction Immunosuppressive Therapy on Long Term Kidney Transplant Function When Measured by Iothalamate Clearance

  2020cites this paper
• Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience.

  2020cites this paper
• Immunosuppression and Treatment of Rejection in Uterus Transplantation: Current Practice and Future Potential

  2019cites this paper
• Comparing the effect of induction therapy with or without antithymocyte globulin on renal allograft outcomes in live-donor kidney transplant recipients

  2019cites this paper
• Comparison of Alemtuzumab Versus Basiliximab Induction Therapy in Elderly Kidney Transplant Recipients: A Single-Center Experience

  2019cites this paper
• Alemtuzumab Induction Versus Conventional Immunosuppression in Heart Transplant Recipients

  2019cites this paper
• Perioperative Care for Kidney Transplant Recipients

  2019cites this paper
• Alemtuzumab

  2018cites this paper
• Interventions for treating antibody‐mediated acute rejection in kidney transplant recipients

  2018cites this paper
• Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis.

  2018cites this paper
• Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis.

  2018cites this paper
• Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

  2018cites this paper
• Postrenal transplant infection: What is the effect of specific immunosuppressant agents?

  2018cites this paper
• Induction of disease remission with one cycle of alemtuzumab in relapsing–remitting MS

  2018cites this paper
• Monocytes Contribute to High Renal Allograft Rejection Rates when Alemtuzumab is Utilized as an Induction Agent: A Retrospective Study

  2018influential citation
• Diabetes in Kidney Transplant Recipients

  2018cites this paper
• Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation

  2017cites this paper
• Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients

  2017cites this paper
• Risk factors and outcomes of delayed graft function in renal transplant recipients receiving a steroid sparing immunosuppression protocol

  2017cites this paper
• Alemtuzumab dose adjusted for body weight is associated with earlier lymphocyte repletion and less infective episodes in the first year post renal transplantation – a retrospective study

  2017cites this paper
• Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis

  2017cites this paper
• Seguridad y efectividad de la eliminación linfocitaria en trasplante de manos

  2017cites this paper
• Anti-donor regulatory T cell therapy in liver transplantation.

  2017cites this paper
• Changing Paradigms in the Management of Rejection in Kidney Transplantation

  2017cites this paper
• Live Donor Kidney Transplantation Pearls: A Practical Review

  2017cites this paper
• Induction Immunosuppression in Kidney Transplantation

  2017cites this paper
• Biologics in Transplantation (Anti-thymocyte Globulin, Belatacept, Alemtuzumab): How Should We Use Them?

  2017cites this paper
• m-TOR Inhibitors in Kidney Transplantation: A Comprehensive Review

  2017cites this paper
• Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation.

  2017cites this paper
• Analysis of Risk Factors for Kidney Retransplant Outcomes Associated with Common Induction Regimens: A Study of over Twelve-Thousand Cases in the United States

  2017cites this paper
• Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up.

  2017cites this paper
• Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis

  2017cites this paper
• Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation

  2017cites this paper
• Effets indésirables des biothérapies dans la sclérose en plaques et les maladies apparentées

  2016cites this paper
• Evolution of Immunosuppressive Agents in Renal Transplantation: An Updated Review

  2016cites this paper
• Alemtuzumab in paediatric kidney transplantation, five years' experience at the Pablo Tobón Uribe Hospital in Medellín, Colombia.

  2016cites this paper
• Prediction, prevention, and management of delayed graft function: where are we now?

  2016cites this paper
• Co-stimulation Blockade Plus T-Cell Depletion in Transplant Patients: Towards a Steroid- and Calcineurin Inhibitor-Free Future?

  2016cites this paper
• Immunomodulator alemtuzumab therapy in kidney transplantation

  2016cites this paper
• Humanized Monoclonal Antibody Alemtuzumab Treatment in Transplant.

  2016cites this paper
• Basiliximab in High-risk Group: An African View

  2016cites this paper
• Update on the intraoperative management of adult cadaveric renal transplantation

  2016cites this paper
• Transplantation Immunology: Kidney and Liver

  2016cites this paper
• Immunosuppression and Results in Renal Transplantation

  2016cites this paper
• Alemtuzumab en trasplante renal pediátrico: experiencia de 5 años en el Hospital Pablo Tobón Uribe de Medellín, Colombia

  2016cites this paper
• Effetti collaterali delle bioterapie nella sclerosi multipla e nelle malattie correlate

  2016cites this paper
• Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects

  2016cites this paper
• Impact of Immune-Modulatory Drugs on Regulatory T Cell

  2016cites this paper
• Letter to the EditorAlemtuzumab in paediatric kidney transplantation, five years’ experience at the Pablo Tobón Uribe Hospital in Medellín, ColombiaAlemtuzumab en trasplante renal pediátrico: experiencia de 5 años en el Hospital Pablo Tobón Uribe de Medellín, Colombia☆

  2016cites this paper
• A systematic review of the use of rituximab as induction therapy in renal transplantation.

  2015cites this paper
• Immunosuppression and Post-transplant Hyperglycemia.

  2015cites this paper
• Renal transplantation in 2014: Renal transplantation—reducing risk and improving outcome

  2015cites this paper
• Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction

  2015cites this paper
• The search for the optimal antibody induction strategy in kidney transplantation: still “hazy” after all these years

  2015cites this paper
• Avoiding immunological rejection in regenerative medicine.

  2015cites this paper
• Alemtuzumab (Campath-1H) experience in kidney transplantation what we have learned; current practices; and scope for the future?

  2015cites this paper
• Daclizumab Versus Rabbit Antithymocyte Globulin in High‐Risk Renal Transplants: Five‐Year Follow‐up of a Randomized Study

  2015cites this paper
• Renal Transplantation Clinical Trials: A Critical Appraisal

  2015cites this paper
• Fungal Infections in the Era of Biologic Therapies

  2015cites this paper
• Biologika als Immunsuppressiva bei Nierentransplantation

  2014cites this paper
• New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin®) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity

  2014cites this paper
• Malignancies: pre and post transplantation strategies.

  2014cites this paper
• In search of an optimal induction agent in kidney transplantation.

  2014cites this paper
• Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.

  2014cites this paper
• Diagnosis and Management of Antibody-Mediated Rejection: Current Status and Novel Approaches

  2014cites this paper
• Randomized Trial of Three Induction Antibodies in Kidney Transplantation: Long-Term Results

  2014cites this paper
• Managing End-Stage Renal Disease in Older Patients: A Single Centre Experience with Renal Transplantation in the Elderly

  2014cites this paper
• Erratum to: New Directions for Rabbit Antithymocyte Globulin (Thymoglobulin®) in Solid Organ Transplants, Stem Cell Transplants and Autoimmunity

  2014cites this paper
• Proceedings From an International Consensus Meeting on Posttransplantation Diabetes Mellitus: Recommendations and Future Directions

  2014cites this paper
• Biologika als Immunsuppressiva bei Nierentransplantation

  2014cites this paper
• Early Corticosteroid Avoidance in Kidney Transplant Recipients Receiving ATG‐F Induction: 5‐Year Actual Results of a Prospective and Randomized Study

  2014cites this paper
• What's new in clinical solid organ transplantation by 2013.

  2014cites this paper
• Immunosuppressive drugs after solid organ transplantation.

  2013cites this paper
• Systematic reviews of alemtuzumab in renal transplantation.

  2013cites this paper
• Infectious Complications of Immune Modulatory Agents

  2013cites this paper
• Re: letter to the editor on "Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review".

  2013cites this paper
• Alemtuzumab Induction in Renal Transplantation Permits Safe Steroid Avoidance with Tacrolimus Monotherapy: A Randomized Controlled Trial

  2013cites this paper
• Managing Transplant Rejection in the Elderly: The Benefits of Less Aggressive Immunosuppressive Regimens

  2013cites this paper
• Thymoglobulin and Its Use in Renal Transplantation: A Review

  2013cites this paper
• Is it time to give up with calcineurin inhibitors in kidney transplantation?

  2013cites this paper
• Current trends in immunosuppression following organ transplantation in children

  2013cites this paper
• Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol

  2013cites this paper